



March 2026 Grand Rounds: Breaking the Obesity-Cancer Link: Weighing in on GLP-1RAs

Credit for this course may not exceed 1 credit when both the live and enduring material activity format credits are combined.

Live Course Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this live activity for a maximum of 1 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

On-Demand Course Accreditation and Credit for Physicians

The Obesity Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Obesity Society designates this enduring material for a maximum of 1 *AMA PRA Category 1 Credit*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Important Dates for On-Demand Course (Enduring Material)

Date of Release: April 15, 2026

Date of Termination: December 31, 2028

Learning Objectives

At the conclusion of this activity, participants should be able to:

1. Describe the mechanistic links between obesity and cancer, including the roles of metabolic dysfunction, chronic inflammation, and immune dysregulation in tumor development and progression.
2. Evaluate the evidence for weight-loss interventions, including dietary strategies, bariatric surgery, and GLP-1 receptor agonists, and their potential to influence obesity-related cancer pathways and inform approaches to cancer prevention and treatment.

Commercial Support

No commercial support was received for this activity.

Faculty and Planning Committee Disclosure Information

The Obesity Society adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities¹ (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

The Obesity Society asks all individuals involved in the development and presentation of Continuing Medical Education (CME) activities to disclose all relevant relationships with ineligible companies. This information is disclosed to CME activity participants. The Obesity Society has procedures to mitigate all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals or devices is being discussed. In the list below, the nature of the relationship and company are followed by the industry of that company.

Chairs:

At TOS activities, course/session chairs are responsible for timekeeping, introductions, housekeeping announcements, and presenting audience questions to speakers. TOS has determined that chairs do not have the ability to influence content. Accordingly, TOS does not collect, mitigate, or disclose relevant financial relationships of chairs (unless they have a dual role as a planner or speaker).

Panelists and Speakers:

Panelists are speakers who speak without presenting slides in a portion of a session or course. As speakers, they are required to disclose, and their relevant financial relationships are listed below. All speakers - with or without relevant financial relationships, with or without slides - are advised, and subsequently attest that "The content and/or

¹ An ineligible company as defined by the ACCME is one that is not eligible for ACCME accreditation, in other words those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include: 1) Advertising, marketing, or communication firms whose clients are ineligible companies, 2) Bio-medical startups that have begun a governmental regulatory approval process, 3) Compounding pharmacies that manufacture proprietary compound, 4) Device manufacturers or distributors, 5) Diagnostic labs that sell proprietary products, 6) Growers, distributors, manufacturers or sellers of medical foods and dietary supplements, 7) Manufacturers of health-related wearable products, 8) Pharmaceutical companies or distributors, 9) Pharmacy benefit managers, 10) Reagent manufacturers or sellers. Reference: <https://accme.org/faq/what-accmes-definition-ineligible-company>

presentation of the information with which I am involved will promote quality or improvements in health care and will not promote a specific proprietary business interest or a commercial interest (including ACCME-defined ineligible companies). Content for this activity, including any presentation of therapeutic options, will be balanced, evidence-based and commercially unbiased.”

Speaker Disclosures:

Stephen Hursting, PhD, MPH	No relevant financial relationships.
----------------------------	--------------------------------------

Planner Disclosures:

Sriram Machenini, MD	No relevant financial relationships
----------------------	-------------------------------------

Reviewer Disclosures: No members of the TOS CME Oversight Committee, charged with the resolution of all relevant conflicts of interest, had any relevant financial relationships while serving on the committee.

Bibliography

1. Kong W, Deng B, Shen X, John C, Haag J, Sinha N, Lee D, Sun W, Chen S, Zhang H, Clontz A, Hursting SD, Zhou C, Bae-Jump V. Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer. *Gynecol Oncol.* 2024 Dec;191:116-123. doi: 10.1016/j.ygyno.2024.10.004. Epub 2024 Oct 10. PMID: 39388742; PMCID: PMC12419173.
2. Camp KK, Coleman MF, McFarlane TL, Doerstling SS, Khatib SA, Rezeli ET, Lewis AG, Pfeil AJ, Smith LA, Bowers LW, Fouladi F, Gong W, Glennly EM, Parker JS, Milne GL, Carroll IM, Fodor AA, Seeley RJ, Hursting SD. Calorie restriction outperforms bariatric surgery in a murine model of obesity and triple-negative breast cancer. *JCI Insight.* 2023 Sep 12;8(19):e172868. doi: 10.1172/jci.insight.172868. PMID: 37698918; PMCID: PMC10629811.
3. Valencia-Rincón E, Rai R, Chandra V, Wellberg EA. GLP-1 receptor agonists and cancer: current clinical evidence and translational opportunities for preclinical research. *J Clin Invest.* 2025 Nov 3;135(21):e194743. doi: 10.1172/JCI194743. PMID: 41178720; PMCID: PMC12578377.
4. Hursting SD. Obesity, energy balance, and cancer: a mechanistic perspective. *Cancer Treat Res.* 2014;159:21-33. doi: 10.1007/978-3-642-38007-5_2. PMID: 24114472.

Disclaimer

These materials and all other materials provided in conjunction with continuing medical education activities are intended solely for the purposes of supplementing continuing medical education programs for qualified health care professionals. Anyone using the materials assumes full responsibility and all risk for their appropriate use. The Obesity Society makes no warranties or representations whatsoever regarding the accuracy, completeness, currentness, noninfringement, merchantability or fitness for a particular purpose of the materials. In no event will The Obesity Society be liable to anyone for any decision made or action taken in reliance on the materials. In no event should the information in the materials be used as a substitute for professional care.

This document was last updated March 13, 2026